{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:31:12Z","timestamp":1787725872733,"version":"build-2784847793"},"reference-count":39,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007408","name":"Medical Center, University of Pittsburgh","doi-asserted-by":"publisher","award":["P30CA047904"],"award-info":[{"award-number":["P30CA047904"]}],"id":[{"id":"10.13039\/100007408","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA229431"],"award-info":[{"award-number":["R01CA229431"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jpet.2025.103769","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T01:12:41Z","timestamp":1762218761000},"page":"103769","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Lysine demethylase 5D promotes CHEK1 inhibitor sensitivity through p38-mediated cyclooxygenase-2 expression in castration-resistant prostate cancer cells"],"prefix":"10.1016","volume":"392","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4021-2409","authenticated-orcid":false,"given":"Wenxiao","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shichen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Raymond E.","family":"West","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ella R.","family":"Donahue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4339-1382","authenticated-orcid":false,"given":"Thomas D.","family":"Nolin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9502-4851","authenticated-orcid":false,"given":"Qiming Jane","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jpet.2025.103769_bib1","doi-asserted-by":"crossref","first-page":"795","DOI":"10.3390\/cancers13040795","article-title":"Clinical candidates targeting the ATR-CHK1-WEE1 axis in cancer","volume":"13","author":"Gorecki","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jpet.2025.103769_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1150777","article-title":"A review of treatments targeting DNA-repair gene defects in metastatic castration resistant prostate cancer","volume":"13","author":"Maslov","year":"2023","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.jpet.2025.103769_bib3","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41391-019-0153-2","article-title":"Role of the DNA damage response in prostate cancer formation, progression and treatment","volume":"23","author":"Zhang","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"21","key":"10.1016\/j.jpet.2025.103769_bib4","doi-asserted-by":"crossref","first-page":"8273","DOI":"10.3390\/ijms21218273","article-title":"Targeting DNA damage response in prostate and breast cancer","volume":"21","author":"Wengner","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.jpet.2025.103769_bib5","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.18632\/oncotarget.4919","article-title":"The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and E\u03bc-MYC driven B-cell lymphoma","volume":"7","author":"Walton","year":"2016","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.jpet.2025.103769_bib6","doi-asserted-by":"crossref","first-page":"5221","DOI":"10.1021\/acs.jmedchem.5b01938","article-title":"Multiparameter lead optimization to give an oral checkpoint kinase 1 (CHK1) inhibitor clinical candidate: (R)-5-((4-((morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737)","volume":"59","author":"Osborne","year":"2016","journal-title":"J Med Chem"},{"issue":"1","key":"10.1016\/j.jpet.2025.103769_bib7","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41416-023-02279-x","article-title":"A phase 1\/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer","volume":"129","author":"Kristeleit","year":"2023","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.jpet.2025.103769_bib8","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1158\/1078-0432.CCR-22-2074","article-title":"A phase I\/II trial of oral SRA737 (a Chk1 inhibitor) given in combination with low-dose gemcitabine in patients with advanced cancer","volume":"29","author":"Jones","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"21","key":"10.1016\/j.jpet.2025.103769_bib9","doi-asserted-by":"crossref","first-page":"5567","DOI":"10.1158\/1078-0432.CCR-20-1741","article-title":"X- and Y-linked chromatin-modifying genes as regulators of sex-specific cancer incidence and prognosis","volume":"26","author":"Tricarico","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.jpet.2025.103769_bib10","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/ijc.31881","article-title":"KDM5 demethylases and their role in cancer cell chemoresistance","volume":"144","author":"Plch","year":"2019","journal-title":"Int J Cancer"},{"issue":"4","key":"10.1016\/j.jpet.2025.103769_bib11","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/S0022-5347(05)67774-9","article-title":"Deletion of Y-chromosome specific genes in human prostate cancer","volume":"163","author":"Perinchery","year":"2000","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.jpet.2025.103769_bib12","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.153768","article-title":"Mosaic loss of chromosome Y promotes leukemogenesis and clonal hematopoiesis","volume":"7","author":"Zhang","year":"2022","journal-title":"JCI Insight"},{"issue":"12","key":"10.1016\/j.jpet.2025.103769_bib13","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1158\/1078-0432.CCR-13-3296","article-title":"Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer","volume":"20","author":"Liu","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.jpet.2025.103769_bib14","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1158\/1535-7163.MCT-13-0208","article-title":"Inhibition of ABCB1 expression overcomes acquired docetaxel resistance in prostate cancer","volume":"12","author":"Zhu","year":"2013","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"10.1016\/j.jpet.2025.103769_bib15","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1158\/0008-5472.CAN-14-3080","article-title":"Intracrine androgens and AKR1C3 activation confer resistance to enzalutamide in prostate cancer","volume":"75","author":"Liu","year":"2015","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.jpet.2025.103769_bib16","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/s41388-024-02939-z","article-title":"Synthetic lethal combination of CHK1 and WEE1 inhibition for treatment of castration-resistant prostate cancer","volume":"43","author":"Chao","year":"2024","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.jpet.2025.103769_bib17","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nm.4045","article-title":"Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer","volume":"22","author":"Beltran","year":"2016","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.jpet.2025.103769_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0107468","article-title":"pRRophetic: an R package for prediction of clinical chemotherapeutic response from tumor gene expression levels","volume":"9","author":"Geeleher","year":"2014","journal-title":"PLoS One"},{"issue":"Database issue","key":"10.1016\/j.jpet.2025.103769_bib18","first-page":"D955","article-title":"Genomics of drug sensitivity in cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells","volume":"41","author":"Yang","year":"2013","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"10.1016\/j.jpet.2025.103769_bib19","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00280-014-2380-5","article-title":"Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors","volume":"73","author":"Sausville","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.jpet.2025.103769_bib20","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.ejmech.2018.03.075","article-title":"Synthesis and biological evaluation of 2,6-disubstituted-9H-purine, 2,4-disubstitued-thieno[3,2-d]pyrimidine and -7H-pyrrolo[2,3-d]pyrimidine analogues as novel CHK1 inhibitors","volume":"151","author":"Tian","year":"2018","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.jpet.2025.103769_bib22","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/1471-2105-7-123","article-title":"Detecting outliers when fitting data with nonlinear regression \u2013 a new method based on robust nonlinear regression and the false discovery rate","volume":"7","author":"Motulsky","year":"2006","journal-title":"BMC Bioinformatics"},{"issue":"29","key":"10.1016\/j.jpet.2025.103769_bib23","doi-asserted-by":"crossref","first-page":"9744","DOI":"10.3748\/wjg.v20.i29.9744","article-title":"p38\u03b1 MAPK pathway: a key factor in colorectal cancer therapy and chemoresistance","volume":"20","author":"Grossi","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"5","key":"10.1016\/j.jpet.2025.103769_bib24","doi-asserted-by":"crossref","first-page":"5683","DOI":"10.1002\/jcp.27411","article-title":"Cyclooxygenase-2 in cancer: a review","volume":"234","author":"Hashemi Goradel","year":"2019","journal-title":"J Cell Physiol"},{"issue":"9","key":"10.1016\/j.jpet.2025.103769_bib25","article-title":"The dual function of KDM5C in both gene transcriptional activation and repression promotes breast cancer cell growth and tumorigenesis","volume":"8","author":"Shen","year":"2021","journal-title":"Adv Sci (Weinh)"},{"issue":"2","key":"10.1016\/j.jpet.2025.103769_bib26","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.18632\/oncotarget.6482","article-title":"ATR-Chk1 signaling inhibition as a therapeutic strategy to enhance cisplatin chemosensitivity in urothelial bladder cancer","volume":"7","author":"Li","year":"2016","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.jpet.2025.103769_bib27","doi-asserted-by":"crossref","first-page":"6572","DOI":"10.1074\/jbc.M707568200","article-title":"ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis","volume":"283","author":"Pabla","year":"2008","journal-title":"J Biol Chem"},{"issue":"7","key":"10.1016\/j.jpet.2025.103769_bib28","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1172\/JCI96769","article-title":"ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5D","volume":"128","author":"Komura","year":"2018","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.jpet.2025.103769_bib29","first-page":"117","article-title":"Investigation of histone lysine-specific demethylase 5D KDM5D) isoform expression in prostate cancer cell lines: a system approach","volume":"20","author":"Jangravi","year":"2016","journal-title":"Iran Biomed J"},{"issue":"9","key":"10.1016\/j.jpet.2025.103769_bib30","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.1021\/acs.jproteome.5b00333","article-title":"Two splice variants of Y chromosome-located lysine-specific demethylase 5D have distinct function in prostate cancer cell line (DU-145)","volume":"14","author":"Jangravi","year":"2015","journal-title":"J Proteome Res"},{"issue":"22","key":"10.1016\/j.jpet.2025.103769_bib31","doi-asserted-by":"crossref","first-page":"6259","DOI":"10.1073\/pnas.1600420113","article-title":"Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression","volume":"113","author":"Komura","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.jpet.2025.103769_bib32","doi-asserted-by":"crossref","first-page":"5310","DOI":"10.3390\/ijms24065310","article-title":"KDM5D histone demethylase identifies platinum-tolerant head and neck cancer cells vulnerable to mitotic catastrophe","volume":"24","author":"Chen","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"50","key":"10.1016\/j.jpet.2025.103769_bib33","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2402022121","article-title":"KDM5D histone demethylase mediates p38\u03b1 inactivation via its enzymatic activity to inhibit cancer progression","volume":"121","author":"Chen","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.jpet.2025.103769_bib34","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.molonc.2013.08.012","article-title":"Dual specificity phosphatase 1 expression inversely correlates with NF-\u03baB activity and expression in prostate cancer and promotes apoptosis through a p38 MAPK dependent mechanism","volume":"8","author":"Gil-Araujo","year":"2014","journal-title":"Mol Oncol"},{"issue":"1","key":"10.1016\/j.jpet.2025.103769_bib35","first-page":"217","article-title":"Profiling of signaling molecules in four different human prostate carcinoma cell lines before and after induction of apoptosis","volume":"28","author":"Skj\u00f8th","year":"2006","journal-title":"Int J Oncol"},{"issue":"12","key":"10.1016\/j.jpet.2025.103769_bib36","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1002\/jcb.25600","article-title":"Resistance to 3-HTMC-induced apoptosis through activation of PI3K\/Akt, MEK\/ERK, and p38\/COX-2\/PGE2 pathways in human HT-29 and HCT116 colorectal cancer cells","volume":"117","author":"Semaan","year":"2016","journal-title":"J Cell Biochem"},{"issue":"13","key":"10.1016\/j.jpet.2025.103769_bib37","first-page":"3632","article-title":"Cyclooxygenase-2 is up-regulated by interleukin-1 beta in human colorectal cancer cells via multiple signaling pathways","volume":"63","author":"Liu","year":"2003","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.jpet.2025.103769_bib38","doi-asserted-by":"crossref","first-page":"4915","DOI":"10.1158\/0008-5472.CAN-06-3952","article-title":"P-glycoprotein mediates celecoxib-induced apoptosis in multiple drug-resistant cell lines","volume":"67","author":"Fantappi\u00e8","year":"2007","journal-title":"Cancer Res"},{"issue":"5B","key":"10.1016\/j.jpet.2025.103769_bib39","first-page":"2967","article-title":"Positive correlation between cyclooxygenase 2 and the expression of ABC transporters in non-small cell lung cancer","volume":"28","author":"Surowiak","year":"2008","journal-title":"Anticancer Res"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356525402821?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356525402821?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T22:59:05Z","timestamp":1773874745000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356525402821"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":39,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0022356525402821"],"URL":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103769","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lysine demethylase 5D promotes CHEK1 inhibitor sensitivity through p38-mediated cyclooxygenase-2 expression in castration-resistant prostate cancer cells","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103769","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"103769"}}